Company Profile

Guardant Health Stock Price, News & Analysis

Ticker:
GH
Exchange:
NASDAQ
Sector:
Biopharma
Location:
United States

Stock performance

157.58 USD (-3.43%)

Close

Last updated: August 6, 2026

17.3B USD

Market cap

Why the stock is moving

As of Aug 6, 2026, GH closed down 3.43% at $157.58. No new same-company headline was identified in the current news window.

Company overview

Business overview

Guardant Health is a liquid-biopsy company focused on oncology diagnostics for screening, therapy selection, and disease monitoring.

Geographic Base and Sector Classification

Headquartered in the United States and listed on NASDAQ, Guardant sits in precision diagnostics.

Business Model Characteristics

The business depends on test adoption, reimbursement, clinical utility, and the expansion of liquid biopsy into more use cases.

Position Within the Biotechnology Landscape

Guardant is a leading oncology-diagnostics platform whose stock moves on adoption, reimbursement, and product performance.

Future catalysts

Guardant Health's catalysts are Shield screening adoption, Reveal MRD traction, and any reimbursement or launch step that widens the oncology-diagnostics franchise. The company improves when screening and monitoring become more routine in clinical workflows.

Recent news

  1. 01
  2. 02
  3. 03
  4. 04
  5. 05

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

Frequently Asked Questions

What is the current stock price of Guardant Health (GH)?

Guardant Health (GH) most recently closed at 157.58 USD, a -3.43% move versus the previous session.

What is the market cap of Guardant Health (GH)?

Guardant Health currently has a market capitalization of 17.3B USD on BioPharmSignal.

What does Guardant Health do?

Guardant Health is a liquid-biopsy company focused on oncology diagnostics for screening, therapy selection, and disease monitoring.

On which exchange is GH stock listed?

Guardant Health (GH) is associated with NASDAQ, United States, Biopharma.

What is Guardant?

Guardant Health's catalysts are Shield screening adoption, Reveal MRD traction, and any reimbursement or launch step that widens the oncology-diagnostics franchise.

Which conditions is Guardant Health targeting with Guardant?

Guardant Health is associated with oncology based on its company overview and current catalyst commentary.

How does Guardant Health describe recent progress with Guardant?

Guardant Health's catalysts are Shield screening adoption, Reveal MRD traction, and any reimbursement or launch step that widens the oncology-diagnostics franchise.

What is Health?

Guardant Health is a liquid-biopsy company focused on oncology diagnostics for screening, therapy selection, and disease monitoring.